Immunovant’s

Immunovant’s

Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions. Learn more

Launch date
Employees
Market cap
$4.3b
Enterprise valuation
$3.8b (Public information from Sep 2024)
New York City New York (HQ)
Authorizing premium user...